Prime time for intermittent androgen suppression

European Urology

Volumn 66, Issue 2, 2014, Pages 240-242

  Gleave, Martin ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT;

ANDROGEN DEPRIVATION THERAPY; ANDROGEN THERAPY; ANEMIA; CANCER SURVIVAL; EDITORIAL; GENE EXPRESSION; HEALTH CARE QUALITY; HUMAN; LIFE EXPECTANCY; MUSCLE ATROPHY; OSTEOPOROSIS; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; STEROIDOGENESIS; ADENOCARCINOMA; MALE; PATHOLOGY; PROSTATIC NEOPLASMS; SECONDARY;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84904044669     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.05.052     Document Type: Editorial

References (10)

1. M. Gleave, H. Miyake, and K. Chi Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer Cancer Chemother Pharmacol 56 Suppl 1 2005 47 57
2. M. Bolla, D. Gonzalez, and P. Warde et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N Engl J Med 337 1997 295 300
3. E.M. Messing, J. Manola, M. Sarosdy, G. Wilding, E.D. Crawford, and D. Trump Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer N Engl J Med 341 1999 1781 1788
4. J.M. Crook, C.J. O'Callaghan, and G. Duncan et al. Intermittent androgen suppression for rising PSA level after radiotherapy N Engl J Med 367 2012 895 903
5. M. Hussain, C.M. Tangen, and D.L. Berry et al. Intermittent versus continuous androgen deprivation in prostate cancer N Engl J Med 368 2013 1314 1325
6. S.L. Goldenberg, N. Bruchovsky, M.E. Gleave, L.D. Sullivan, and K. Akakura Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report Urology 45 1995 839 845
7. F. Calais da Silva, F.M. Calais da Silva, and F. Gonçalves et al. Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group Eur Urol 66 2014 232 239
8. C.A. Berrevoets, A. Umar, and A.O. Brinkmann Antiandrogens: selective androgen receptor modulators Mol Cell Endocrinol 198 2002 97 103
9. S. Appu, N. Lawrentschuk, R.J. Grills, and G. Neerhut Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer J Urol 174 2005 140 142
10. P. Warde, M. Mason, K. Ding NCIC CTG PR.3/MRC UK PR07 investigators Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial Lancet 378 2011 2104 2111